Targeted Protein Degraders

PROTACs and molecular glues are a new therapeutic modality with multiple clinical-trial entries. The session covers ARV-471 (vepdegestrant) in ER+ breast cancer, BMS-986365 in androgen-receptor-positive prostate cancer, KT-474 in autoimmune disease, molecular-glue degraders (cereblon-binders like CC-220 iberdomide), ARV-110 (bavdegalutamide) discontinuation lessons, and the regulatory pathway for degraders. Discussion addresses PROTACs vs molecular glues comparison, hook-effect pharmacology, the catalytic stoichiometry advantage, oral bioavailability challenges, intracellular protein-protein-interaction targets newly accessible, and the IP and patent landscape.